There is an ongoing clinical trial investigating the use of human recombinant soluble ACE2 in patients with severe COVID-19, which neutralizes the viral S protein and reduces organ damage by counterbalancing the inflammatory response [58,59]. The gene discussed is PROS1; the disease is COVID-19.